By far the two most common prostate diseases are prostatitis and benign hyperplasia (BPH). Prostatitis can be complicated by BPH or accompany it with periodic exacerbations. Drug therapy is an important component in the general treatment of prostate disease. Furthermore, treatment often ends in failure due to inadequate therapy, missed medications and, when the condition is relieved, ignoring the illness.
Thus, 20-30% of patients are not satisfied with the treatment, do not experience a decrease in the symptoms of urinary disorders and an improvement in their quality of life. This is likely due to an incorrect assessment of lower urinary tract function in men with BPH and therefore the choice of inappropriate treatment.
As you know, prostatitis is acute and chronic (PC), bacterial and non-bacterial.
Prostatitis in %
- acute bacterial prostatitis - 5-10%;
- chronic bacterial prostatitis - 6-10%;
- chronic abacterial prostatitis - 80–90%, including prostatodynia - 20–30%.
The most common is chronic abacterial prostatitis, which must be controlled and exacerbations avoided in a timely manner with and without BPH.
The main drugs for the treatment of BPH and chronic prostatitis:
- 5α-reductase inhibitors (finasteride, dutasteride);
- a-blockers (doxazosin, tamsulosin);
- herbal medicine (salt palm extract);
- amino acid complexes;
- extracts from animal organs (prostate extract);
- entomotherapeutic drugs (insect-derived products).
At the same time, 13-30% of the effect of a-blocker use does not occur within 3 months of treatment - additional drug therapy in this group is not advisable.
When prescribing finasteride, the physician needs to be prepared for the fact that the most significant side effects of the drug: impotence, decreased libido, decreased ejaculation volume can lead to self-withdrawal of the drug by the patient.
The treatment of BPH and prostatitis is an important urological problem, not fully resolved.
The frequent exacerbations of CP, in the absence of an indication for prostate surgery, force the physician to use additional methods in drug treatment. Often, the presence of concomitant CP aggravates the course of BPH, because inflammation occurs in 80% of cases in the prostate with benign hyperplasia.
Modern medicine gives us new opportunities for the treatment of CP and BPH and the prevention of exacerbations.